Results 31 to 40 of about 161,532 (251)

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines

Vaccines, 2023
The combination of mosaic Gag and CAP256 envelope in an HIV vaccine regimen comprising DNA prime and modified vaccinia Ankara (MVA) boost followed by protein boost has previously been shown to generate robust autologous Tier 2 neutralizing antibodies ...
Rosamund Chapman, Michiel van Diepen, Nicola Douglass, Tandile Hermanus, Penny L. Moore, Anna-Lise Williamson   +5 more
doaj   +1 more source

DNA vaccine: Methods and mechanisms

Advances in Human Biology, 2018
Infectious diseases are the biggest cause of mortality and morbidity in humans, especially in poor and developing countries. For many years, no new vaccine has been developed, which indicates the limitations of the development of common vaccines ...
Saber Soltani, Abbas Farahani, Mahsa Dastranj, Navid Momenifar, Parviz Mohajeri, Amir Darb Emamie   +5 more
doaj   +1 more source

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

Pharmaceutics, 2014
Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration.
Yingying Xu, Pak-Wai Yuen, Jenny Ka-Wing Lam   +2 more
doaj   +1 more source

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Vaccines, 2023
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received ...
Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, Deborah Kane, Amha Tadesse, Hyojin Lee, Young K. Park, Kar Muthumani, Christine C. Roberts   +8 more
doaj   +1 more source

Antirabies DNA Immunization

Проблемы особо опасных инфекций, 2010
Cited are literary data related to the development of DNA vaccines against rabies virus. Research results regarding gene vaccination of different models of laboratory animals and different ways of vaccine introduction are presented.
I. V. Tuchkov, A. K. Nikiforov
doaj   +1 more source

Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. [PDF]

PLoS ONE, 2012
Although the use of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection, there are still a number of vaccine recipients who do not develop detectable antibody responses.
Guohong Ge, Shixia Wang, Yaping Han, Chunhua Zhang, Shan Lu, Zuhu Huang   +5 more
doaj   +1 more source

Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study

Frontiers in Immunology, 2022
Current vaccination strategies against influenza focus on generating an antibody response against the viral haemagglutination surface protein, however there is increasing interest in neuraminidase (NA) as a target for vaccine development. A critical tool
Marie-Clotilde Bernard, Joanna Waldock, Sylvie Commandeur, Lea Strauß, Claudia Maria Trombetta, Serena Marchi, Fan Zhou, Serge van de Witte, Peter van Amsterdam, Sammy Ho, Katja Hoschler, Vladimir Lugovtsev, Jerry P. Weir, Emanuele Montomoli, Rebecca J. Cox, Othmar G. Engelhardt, Damien Friel, Ralf Wagner, Thierry Ollinger, Sophie Germain, Hanna Sediri-Schön   +20 more
doaj   +1 more source

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines

Vaccines, 2019
DNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic.
Ashish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans, Branka Grubor-Bauk   +5 more
doaj   +1 more source

Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

Viruses
Single-dose, immunogenic DNA (iDNA) vaccines coding for whole live-attenuated viruses are reviewed. This platform, sometimes called immunization DNA, has been used for vaccine development for flavi- and alphaviruses.
Peter Pushko, Igor S. Lukashevich, Dylan M. Johnson, Irina Tretyakova   +3 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source